Navigation Links
Watson's GELNIQUE(TM) (oxybutynin chloride) Gel 10% Approved by FDA for the Treatment of Overactive Bladder
Date:1/27/2009

ression. The disease affects both men and women however, women experience more severe symptoms earlier in life.

About Watson Pharmaceuticals, Inc.

Watson Pharmaceuticals, Inc. is a global leader in the development and distribution of pharmaceuticals with a broad portfolio of generic products and a specialized portfolio of branded pharmaceuticals focused on Urology, Gynecology and Nephrology (Medical).

In the U.S., the Watson portfolio includes RAPAFLO, Oxytrol(R); Ferrlecit(R), INFeD(R), TRELSTAR(R) LA; and TRELSTAR(R) Depot. In addition, Watson markets the following brands under co-promotion agreements: AndroGel(R), with Solvay Pharmaceuticals, Inc.; Proquin(R) XR, with Depomed, Inc.; Tri-Luma(R) Cream, with Galderma Laboratories; and Femring(R), with Warner Chilcott Limited. The Watson pipeline portfolio includes a number of products, including a six-month formulation of TRELSTAR(R), for the treatment of advanced prostate cancer which is currently under review by the FDA; URACYST(R), under development for cystitis; and a novel new oral contraceptive.

For press releases and other company information, visit the Watson website at http://www.watson.com.

Forward-Looking Statement

Any statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Watson's current perspective of existing trends and information as of the date of this release. Except as expressly required by law, Watson disclaims any intent or obligation to update these forward-looking statements. Actual results may differ materially from Watson's current expectations depending upon a number of factors affecting Watson's business. These factors include, among others, the impact of competitive products and pricing; market acceptance of and continued demand for Watson's prod
'/>"/>

SOURCE Watson Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Biopten (Sapropterin Dihydrochloride) Approved by Japanese Ministry of Health for the Treatment of PKU
2. Shires ELAPRASE(R) (idursulfase) Approved in Japan for the Treatment of Hunter Syndrome
3. Anesiva Outlines Comprehensive Commercialization Plan for FDA Approved Product Zingo(TM)
4. Healthcare Announced That an Overwhelming Majority of its Shareholders Approved the NexGen Biofuels Transaction
5. Bystolic(TM), a Novel Beta Blocker, is Now Approved by the FDA for the Treatment of Hypertension
6. Avastin Approved in Europe for First-Line Treatment of Patients With Advanced Kidney Cancer
7. EVICEL(TM) Fibrin Sealant (Human) Approved for General Hemostasis in Surgery
8. Clexane(R)/Lovenox(R) Approved in Japan
9. Shires ELAPRASE(R) (idursulfase) Approved in Mexico for Treatment of Hunter Syndrome
10. Center for Molecular Medicine Among First to Offer New FDA-Approved Test to Aid in Treatment of Prostate Cancer
11. Lucids VivaScope(R) Reflective Confocal Microscope Approved for Sale in China
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)...  Array BioPharma Inc. (NASDAQ: ARRY ) today ... Novartis Pharma AG to acquire worldwide rights to encorafenib ... This agreement is conditional on the closing of transactions announced ... which are expected to close in the first half ...
(Date:1/22/2015)... January 22, 2015 GEA Niro Soavi ... top laboratory homogenizer, the PandaPLUS 2000, which is ideal ... , and cell disruption . This compact laboratory ... fruit juices, liquid food, food additives and ingredients as ...
(Date:1/22/2015)... 2015 Crystal Diagnostics (CDx) Xpress System, a ... received AOAC-PTM Certifications for the six non-O157 Shiga toxin-producing E. ... referred to as STEC or the “Big-6”) as well as ... (cfu) per 325 g of raw ground beef and raw ...
(Date:1/22/2015)... Selexis SA, a serial innovation company ... (RCBs) used for drug discovery to commercial manufacturing, announced ... Next-Generation Sequencing (NGS) data packages. The NGS ... by ensuring the integrity of the gene, validation of ...
Breaking Biology Technology:Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 2Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 3Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 4Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 5Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 6Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 7GEA Niro Soavi Announces the PandaPLUS 2000 Homogenizer for Processing New Applications for Nanoemulsions and Cell Disruption 2Crystal Diagnostics Awarded AOAC-PTM Accreditation for the Rapid Detection of “Big 6” E.coli Food Pathogens 2Selexis Generated Research Cell Banks Now Fully Sequenced Using Next-Generation Sequencing 2
... to Battelle for submission of proposals to U.S. ... Corgenix Medical Corporation (OTC Bulletin Board: CONX), a ... has announced a collaboration with Battelle, a Columbus, ... focus includes national security. Under the collaboration, Corgenix ...
... in Treatment of Skin InfectionsNEW HAVEN, Conn., Jan. ... "Company"), a development-stage company focused on the discovery ... of antibiotic-resistant infections, today announced positive final results ... novel fluoroquinolone antibiotic, delafloxacin (RX-3341), in the treatment ...
... Neuralstem, Inc. (NYSE Alternext US: CUR) today announced ... for its patent application, number 10/047,352, for Stable ... and Trade Office (USPTO). This patent covers the ... rendering its growth robust and long-lasting. , (Logo: ...
Cached Biology Technology:Corgenix Signs Collaboration With Battelle 2Corgenix Signs Collaboration With Battelle 3Rib-X Pharmaceuticals Announces Positive Phase 2 Study Results for Delafloxacin and a $25 Million Financing 2Rib-X Pharmaceuticals Announces Positive Phase 2 Study Results for Delafloxacin and a $25 Million Financing 3Rib-X Pharmaceuticals Announces Positive Phase 2 Study Results for Delafloxacin and a $25 Million Financing 4Rib-X Pharmaceuticals Announces Positive Phase 2 Study Results for Delafloxacin and a $25 Million Financing 5Neuralstem Receives Final Notice of Allowance for New Stem Cell Immortalization Technology Patent 2Neuralstem Receives Final Notice of Allowance for New Stem Cell Immortalization Technology Patent 3
(Date:1/22/2015)... S.A. ("Company") (BM&FBOVESPA: VLID3 ON), is pleased to inform its ... of Washington,s Department of Licensing, in the United ... system for driver,s licenses and identification cards to its subsidiary, ... will start in January 2015, with enrollment and card production ...
(Date:1/22/2015)... 16, 2015  A man-made form of insulin delivered by ... capabilities in adults with mild cognitive impairment and Alzheimer,s ... researchers at Wake Forest Baptist Medical Center. ... mild cognitive impairment (MCI) or mild to moderate Alzheimer,s ...
(Date:1/22/2015)... and Markets ( http://www.researchandmarkets.com/research/wxdglm/global_wearable ) has ... Technologies Market and Applications, Opportunities, Industry Analysis, Segmentation, ... report to their offering. , ... be worn on the user,s body and have ...
Breaking Biology News(10 mins):Valid USA Signs Contract For Washington Driver's License Issuance 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 3Global Wearable Technologies Market and Applications, Opportunities, Industry Analysis, Segmentation, Size, Growth, Share, Overview, Trends and Forecast 2014-2020 2
... of green foliage around the globe, observed since the ... part from the increasing concentration of carbon dioxide in ... the globe finds that a carbon dioxide "fertilization effect" ... 2010. Focusing on the southwestern corner of North ...
... countries have joined the International Osteoporosis Foundation (IOF) and ... Conference of Osteoporosis Patient Societies. The conference is ... Paasitorni. Osteoporosis, known as the ,silent, ... easily prone to fracture even after a minor bump ...
... that a simple program that uses pedometers to monitor how ... physical activity, decreasing sitting time, a particular problem for office ... if somebody works out 30 minutes a day, the fact ... time for the rest of the day is in and ...
Cached Biology News:Elevated carbon dioxide making arid regions greener 2Elevated carbon dioxide making arid regions greener 3IOF Worldwide Conference of Osteoporosis Patient Societies opens in Helsinki 2Study: Pedometer program helps motivate participants to sit less, move more 2
RABBIT ANTI RAT AQUAPORIN 5...
... Automatic High Sensitivity Laboratory Osmometer for both 0.2 and 2.0 mL samples for ... and record keeping. Bar code reading capability with optional scanner. RS-232 port. ... ... ...
MAb to Hu-IFN-Gamma RC2 (CD118), NON-Neutralizing, Clone MMHGR-2 Binds to but does not neutralize human interferon gamma receptor...
Recombinant Rat CINC-2 alpha, CF...
Biology Products: